standard]
MIRSFLLCSLFFHFIWLQTGLPASNKTNRGRPPTTITKGVNITKPGCQRK
CGNLTVPYPFGVGIGSGCSIDPWFDINCNATFNPPKPFTAKGSLEVIEIS
DSQMRVKNLVAVNCYNQLGNLTMQNPSLRISLPPTFTFSDVNKFTIVGCD
DLALISGRDGSNFTSGCFSLCSAREDLLDGYCTGIGCCQTSIPKGLQSFA
ALLGSVGYHTDVWSFNPCGYTFLAEEESYTFHPSDLQDDTFKNRTIENVP
IVLDWVIGNISCTEAQKANAFTCRENSICTDSDTRLGGYRCSCFEGYEGN
PYLEPGCKDTNECESSPCDPQGFCTNTPGSFICSCPHGFIGDGKKDGRGC
IKQTSPFPAMKFSLGLGFGFLALIIGVTWIYFSIQKRKLIRLRQKFFQQN
GGLLLTQQLSSNDGSLESAKIFSAEELEKATDNYSEDRVLGQGGYGTVYK
GILSDHRVVAIKKSRIMDQSQIEVFINEVVILTQINHRNVVKLLGCCLET
EVPLLVYEYVSNGTLFHHIHNSRTTPWFSWENRLRIATEAAGALAYLHSA
AAMPIIHRDVKSPNILLDEYYTAKISDFGASRLVPIDRTQVTTLVQGTLG
YLDPEYFHTSQLTEKSDVYSFGVVLAELLTGRKPLSTETSEEERNLATYF
IVSIKENRLFQIIEPRLLREGSLEQITAVAELVKRCLKLNGEKRPTMKDV
AMELERLRKYNLRSDQQEENSEVNMAFTADQQLDLYPVPANPQFSTGEYS
GQYSLDTQFLLAINSPR
|
IPR000152; EGF-type aspartate/asparagine hydroxylation site IPR000719; Protein kinase, catalytic domain IPR000742; Epidermal growth factor-like, type 3 IPR001881; EGF-like calcium-binding IPR002290; S |